LON:NCYT Novacyt (NCYT) Share Price, News & Analysis GBX 45.40 +1.60 (+3.65%) As of 05/15/2026 12:39 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsBuy This Stock About Novacyt Stock (LON:NCYT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Novacyt alerts:Sign Up Key Stats Today's Range 44▼ 5050-Day Range 28▼ 77.4052-Week Range 26.60▼ 86Volume1.13 million shsAverage Volume198,480 shsMarket Capitalization£32.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental. The Company is divided into three business segments: Clinical Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas: · Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests · Precision Medicine: DPYD genotyping assay · Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel Instrumentation Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: · Ranger® Technology: automated DNA sample preparation and target enrichment technology MyGo: real-time quantitative PCR (qPCR) instruments Research Use Only Range of services for the life sciences industry: · Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry · Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES) Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV"). For more information, please refer to the website: www.novacyt.com Read More Receive NCYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novacyt and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NCYT Stock News HeadlinesNovacyt announces immediate departure of Chief Scientific OfficerMay 7, 2026 | tipranks.comNovacyt Earnings Call Balances Progress With Cash StrainMay 4, 2026 | tipranks.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.May 16 at 1:00 AM | Porter & Company (Ad)Novacyt Directors Boost Stakes as Molecular Diagnostics Group Expands Global ReachMarch 30, 2026 | tipranks.comNovacyt makes Australian acquisition to accelerate global growthFebruary 23, 2026 | ca.finance.yahoo.comNovacyt S.A. Reports Stable Revenue Amid Strategic GrowthSeptember 30, 2025 | tipranks.comNovacyt Concludes Legal Proceedings with Lab 21 SubsidiarySeptember 12, 2025 | tipranks.comNovacyt Updates on Liquidity Agreement and Share TradingSeptember 1, 2025 | tipranks.comSee More Headlines NCYT Stock Analysis - Frequently Asked Questions How have NCYT shares performed this year? Novacyt's stock was trading at GBX 35.90 on January 1st, 2026. Since then, NCYT shares have increased by 26.5% and is now trading at GBX 45.40. How were Novacyt's earnings last quarter? Novacyt S.A. (LON:NCYT) announced its earnings results on Thursday, April, 30th. The company reported ($33.00) earnings per share for the quarter. The business earned $20.03 million during the quarter. Novacyt had a negative net margin of 135.96% and a negative trailing twelve-month return on equity of 111.34%. How do I buy shares of Novacyt? Shares of NCYT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Novacyt own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novacyt investors own include BP (BP), Global X Cloud Computing ETF (CLOU), genedrive (GDR), Invesco High Yield Equity Dividend Achievers ETF (PEY), boohoo group (BOO). Company Calendar Last Earnings4/30/2026Today5/16/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolLON:NCYT CIKN/A Webwww.novacyt.com Phone33 1 39 46 51 04FaxN/AEmployees120Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£36.80 million Net Margins-135.96% Pretax MarginN/A Return on Equity-111.34% Return on Assets-27.98% Debt Debt-to-Equity Ratio44.73 Current Ratio4.74 Quick Ratio4.46 Sales & Book Value Annual Sales£20.03 million Price / Sales1.64 Cash FlowGBX 78.22 per share Price / Cash Flow0.58 Book ValueGBX 99.62 per share Price / Book0.46Miscellaneous Outstanding Shares72,461,000Free FloatN/AMarket Cap£32.90 million OptionableNot Optionable Beta0.97 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (LON:NCYT) was last updated on 5/16/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredOil is settling in yuan now - here's what that means for goldSaudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novacyt S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novacyt With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
